White Paper

Use Of Payload Core Compounds To Accelerate ADC Clinical Development Timelines

GettyImages-2152418334 3D Rendering Of ADCs

Payloads are crucial in determining the effectiveness of Antibody-Drug Conjugate (ADC) drugs. While over forty natural product classes have been utilized as payloads, most ADCs that have entered the clinic incorporate derivatives of two natural products: dolastatinin 10 and maytansine. The use of these natural products in ADCs has advanced targeted cancer therapy and the development of more effective treatments.

Accessing the desired payload poses challenges for ADC developers due to the complex synthesis process, which is more labor-intensive compared to other small molecules. The use of a GMP-quality payload intermediate as a starting point for payload synthesis enables a more efficient process for research and process development chemists and chemistry, and CMC teams. These intermediate compounds are the core of the active ingredients of Dolastatin 10 and maytansine natural products. Starting the synthetic route with a core compound accelerates the synthesis process, enabling the evaluation of a wider range of compounds. This approach also shortens the synthetic route, expediting the path to clinical trials.

Novel compounds are typically synthesized in-house or with the assistance of a contract development and manufacturing organization (CDMO).

access the White Paper!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Pharmaceutical Online? Subscribe today.

Subscribe to Pharmaceutical Online X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Pharmaceutical Online